Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV20.19 CAR T-cells + Pirtobrutinib in R/R B-cell Malignancies
NCT05990465Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Feb 2025
- Primary completion
- Jul 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of h20.19 CAR T cells and pirtobrutinib in B-cell non-Hodgkin lymphoma, sponsored by Medical College of Wisconsin. Primary endpoints: Number of Adverse Events After CAR 20/19-T Cell Infusion, Number of Adverse Events After Pirtobrutinib Administration in Part A and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
h20.19 CAR T cellspirtobrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05990465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990465.